Authors : Meena Pangarkar, Anand Pathak
DOI : 10.18231/j.ijpo.2020.003
Volume : 7
Issue : 1
Year : 2020
Page No : 10-13
Context: The immunohistochemical (IHC 4) biomarker profile is part of the standard histopathology report
of all newly diagnosed and recurrent cases of carcinoma Breast. This profile is the basis for all neoadjuvant
and adjuvant treatment planning in these cases.
Aims: 1. To study the IHC4 biomarker profile of Carcinoma Breast cases at our Institute.
2. To study the correlation of the five types of molecular subgroups with various clinical and histological
parameters.
Settings and Design: 271 cases of carcinoma breast diagnosed and treated at our Institute, during the
period 1st July 2017 till 30th June 2018.
This is a prospective, observational study.
Materials and Methods: All the cases of biopsy proven carcinoma Breast were subjected to
immunohistochemical staining for four markers- ER, PR, Her 2, and Ki 67.
Fo rmalin Fixed Paraffin Embedded tumor tissue was stained for 4 biomarkers and scored with appropriate
method. (Interpretive Guide: ASCO - CAP Test Guidelines Recommendations 2013)
Manual method of staining was employed, using commercially available reagents.
The cases were classified into five molecular subtypes.
Results: Triple negative breast carcinoma was the most frequent subgroup, followed by the luminal B and
A types and the Her2 enriched cases were lowest in number.
A few cases showed triple positive staining pattern.
Conclusions: The IHC 4 biomarker findings in every case of carcinoma has a direct impact on the treatment
decision making and also on risk stratification of the patients.
Keywords: IHC 4, ER, PR, Her2, Ki67, Carcinoma breast.